Souders Financial Advisors Sells 4,563 Shares of Johnson & Johnson (NYSE:JNJ)

Souders Financial Advisors reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 68.9% in the 1st quarter, Holdings Channel reports. The fund owned 2,064 shares of the company’s stock after selling 4,563 shares during the quarter. Souders Financial Advisors’ holdings in Johnson & Johnson were worth $327,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Christopher J. Hasenberg Inc acquired a new stake in Johnson & Johnson during the 1st quarter worth approximately $31,000. Keener Financial Planning LLC bought a new stake in Johnson & Johnson in the 4th quarter valued at $40,000. WFA Asset Management Corp increased its holdings in Johnson & Johnson by 61.4% during the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 97 shares in the last quarter. Vermillion & White Wealth Management Group LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $44,000. Finally, Disciplined Equity Management Inc. bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $45,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ traded down $1.16 on Thursday, hitting $155.42. The company had a trading volume of 9,309,939 shares, compared to its average volume of 7,328,903. The stock has a market cap of $374.05 billion, a price-to-earnings ratio of 9.77, a P/E/G ratio of 2.54 and a beta of 0.52. The stock has a 50 day moving average price of $148.15 and a 200 day moving average price of $153.39. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $175.97. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The business had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. During the same quarter in the prior year, the business earned $2.80 EPS. Johnson & Johnson’s quarterly revenue was up 4.3% on a year-over-year basis. Analysts expect that Johnson & Johnson will post 10.49 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.19%. The ex-dividend date is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is 30.92%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on JNJ shares. TD Cowen decreased their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a report on Thursday. TD Securities decreased their target price on shares of Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday. HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their price target for the company from $169.00 to $170.00 in a research note on Thursday, April 18th. Royal Bank of Canada restated an “outperform” rating and set a $175.00 price objective on shares of Johnson & Johnson in a research note on Thursday. Finally, The Goldman Sachs Group initiated coverage on Johnson & Johnson in a research report on Thursday, May 30th. They issued a “neutral” rating and a $160.00 target price on the stock. Eight analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $175.29.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.